Table 2 Characteristics of studies investigating the effects of low-dose BCG
First author, yr | Design, LOE | No. of Case/Control | Age Case/Control* | Disease category | Follow-up, mo Case/Control* | Strain | Treatment dose (mg) Case/Control | Maintenance** Case/Control |
|---|---|---|---|---|---|---|---|---|
Ojea 2007 [25] | RCT, 1b | 139/142 | 64.9/65.1 | Intermediate-Risk NMIBC | 61.2/57.3 | Connaught | 13.5/27 | Yes/Yes |
Yalcinkaya 1998 [7] | RCT, 1b | 25/25 | 56.3/55.3 | Superficial BCa | 26.8/31.6 | Connaught | 54/81 | No/No |
Kumar 2002 [6] | RCT, 2b | 13/13 | 55.9/56.7 | NMIBC without CIS | 24(12–30) | Danish 1331 | 40/120 | No/No |
Oddens 2013 [28] | RCT, 1b | 678/677 | 68.0/67.0 | Intermediate and high risk NMIBC | 85.2 | OncoTice | 27/81 | Yes/Yes |
Takashi 1995 [27] | R, 2b | 37/37 | 68.1/61.4 | Superficial BCa | 32 | Tokyo 172 | 40/80 | No/No |
Yoneyama 2008 [5] | R, 2b | 65/85 | 68.3/65.5 | NMIBC without CIS | 42.2/90.7 | Tokyo 172 | 40/80 | No/No |
Irie 2003 [26] | R, 2b | 41/39 | 61.6/62.2 | Superficial BCa | 27.5/20.0 | Tokyo 172 | 40/80 | No/No |